In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to […]
Achillion slumps 33% on potential safety issue with PNH candidate ACH-4471 Read Here Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan Read Here Akari Therapeutics […]
The discovery of how the proteins in a tick’s saliva stop a human’s immune system from running amok could be the answer to treating life-threatening blood disorders, researchers say. Read […]
The study of 75 women showed that eculizumab provided benefit for women with PNH during pregnancy, as evidenced by a high rate of fetal survival and a low rate of […]